How long melanoma takes to become fatal depends almost entirely on when it’s caught. Melanoma discovered while still confined to the skin has a 5-year survival rate of essentially 100%. Once it spreads to distant organs, that number drops to 34%. The timeline from diagnosis to death can range from months to decades, and in many cases, it never happens at all.
Survival by Stage at Diagnosis
The most useful way to understand melanoma’s timeline is through staging. The SEER cancer database, which tracks outcomes across the United States, breaks survival into three categories based on how far the cancer has spread at the time of diagnosis.
- Localized (confined to the skin): 5-year survival is 100%. The vast majority of melanomas are caught at this stage, and most people are effectively cured with surgery alone.
- Regional (spread to nearby lymph nodes or tissue): 5-year survival is 76%. Treatment is more intensive, but most patients still survive long-term.
- Distant (spread to organs like the brain, lungs, or liver): 5-year survival is 34%. This is the stage where melanoma becomes life-threatening on a timeline of months to a few years.
These numbers come from cases diagnosed between 2016 and 2022, meaning they reflect relatively modern treatment approaches. For people diagnosed today with access to the latest therapies, outcomes at every stage are likely somewhat better than these figures suggest.
How Fast Melanoma Grows
Not all melanomas move at the same speed. The most common type, superficial spreading melanoma, grows at a median rate of about 0.12 mm per month. At that pace, a thin melanoma could take many months or even years to reach a dangerous thickness. Lentigo maligna melanoma, which tends to appear on sun-damaged skin in older adults, grows at a similar rate of about 0.13 mm per month.
Nodular melanoma is the exception. It grows roughly four times faster, at about 0.49 mm per month, and tends to grow downward into the skin rather than spreading across the surface. This makes it harder to catch early and more likely to reach deeper tissue quickly. Nodular melanomas account for a disproportionate share of melanoma deaths precisely because of this rapid vertical growth.
Thickness matters because it directly predicts whether the cancer has had the opportunity to reach blood vessels and lymph channels beneath the skin. A melanoma less than 1 mm thick rarely metastasizes. Once it exceeds 4 mm, the risk of spread climbs sharply.
Melanomas That Are Easy to Miss
Some melanomas don’t look like the dark, irregular moles most people are taught to watch for. Amelanotic melanomas lack the typical dark pigment, often appearing pink, red, or skin-colored. Because they don’t match the classic warning signs, they’re frequently diagnosed later. About 27% of amelanotic melanoma patients already have regional or distant spread at diagnosis, compared to just 12% of patients with pigmented melanomas.
This delay has real consequences. Five-year disease-specific survival for amelanotic melanoma is 78.6%, compared to 91.3% for pigmented melanoma. Even after adjusting for age, sex, and stage, patients with amelanotic melanoma carry a 31% higher risk of dying from their cancer. Men and adults over 85 face the highest risk within this group.
What Happens When Melanoma Spreads
Melanoma that reaches distant organs tends to target the brain, lungs, liver, and bone. Up to 60% of patients with advanced melanoma eventually develop brain metastases, which carry some of the worst outcomes. Median survival after a melanoma brain metastasis diagnosis is roughly 4 to 6 months. The number of organs involved matters enormously: one-year survival is 36% with a single organ affected, drops to 13% with two organs, and falls to just 1% with three or more.
Advanced melanoma produces symptoms that reflect where it has spread. Swollen or hard lymph nodes, unexplained weight loss, persistent fatigue, and pain are common. Swollen lymph nodes in the neck can make swallowing difficult. When cancer blocks lymph drainage, fluid accumulates in the surrounding tissue, causing visible swelling called lymphoedema.
How Modern Treatment Has Changed the Timeline
Before immunotherapy became widely available, stage IV melanoma had a median survival of about 8 months. That number has nearly doubled to around 15 months with current treatments. For stages III and IV combined, the picture is even more striking: median overall survival jumped from about 36 months to nearly 78 months in the immunotherapy era. Five-year survival for stage IV disease rose from 14% to 31%.
These improvements come largely from drugs that help the immune system recognize and attack melanoma cells. Some patients with advanced melanoma now survive 10 years or longer on these therapies, something that was essentially unheard of two decades ago. The catch is that these treatments don’t work for everyone, and racial and socioeconomic disparities in access to care mean the benefits aren’t evenly distributed.
Recurrence Can Happen Years Later
Even after successful treatment, melanoma can return. Most recurrences happen within the first three years, but a study of nearly 5,000 melanoma patients found that more than 1 in 20 experienced a recurrence 10 or more years after their initial diagnosis. Out of 4,731 patients with long-term follow-up, 408 had a late recurrence after being disease-free for a decade or longer.
There’s a silver lining to late recurrence: patients whose melanoma comes back after 10 years tend to survive longer after that recurrence than patients whose cancer returns within the first three years. Late recurrences were also somewhat less likely to occur in men, with 57% of late-recurrence patients being male compared to 66% of early-recurrence patients. This long tail of risk is why dermatologists recommend ongoing skin checks for years, sometimes indefinitely, after a melanoma diagnosis.
The Short Answer
A thin melanoma caught early and removed surgically may never pose a threat to your life. A fast-growing nodular melanoma that goes unnoticed could reach dangerous thickness in a matter of months. Once melanoma has metastasized to the brain or multiple organs, survival without treatment is often measured in months. With modern immunotherapy, some patients with advanced disease now live years beyond what was previously possible, though the outcome varies widely from person to person.